X4 PHARMACEUTICALS, INC Debt Instrument, Unamortized Discount (Premium), Net
X4 PHARMACEUTICALS, INC (XFOR) had Debt Instrument, Unamortized Discount (Premium), Net of $283.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet · last filed 2026-08-06
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium), Net $283.00K.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium), Net $349.00K.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium), Net $412.00K.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium), Net $475.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium), Net |
|---|---|
| 2026-06-30 | $283.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $349.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $412.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $475.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $536.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $594.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $650.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $706.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $759.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $825.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $917.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $1.01M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $858.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $767.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $196.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $221.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $238.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$127.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$277.00K 10-K · filed 2023-03-21 |
| 2021-09-30 | -$266.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$253.00K 10-Q · filed 2021-08-03 |
| 2021-03-31 | -$237.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$223.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | -$229.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$234.00K 10-Q · filed 2020-08-04 |
| 2020-03-31 | -$238.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $317.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |